ABL Bio

ISIN KR7298380007

 | 

WKN A2PAUP

Market cap (in EUR)
5,899 m
Country
South Korea
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company was founded by Sang-Hoon Lee on February 16, 2016 and is headquartered in Seongnam-si, South Korea.
Show more Show less
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals South Korea

Financials

Key metrics

Market capitalisation, EUR 5,899 m
EPS, EUR -0.35
P/B ratio 50.3
P/E ratio 37.6
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 23 m
Net income, EUR -38 m
Profit margin -166.24%

What ETF is ABL Bio in?

There are 4 ETFs which contain ABL Bio. All of these ETFs are listed in the table below. The ETF with the largest weighting of ABL Bio is the iShares MSCI Emerging Markets Small Cap UCITS ETF.
ETF Weight Investment focus Fund size (in m EUR)
iShares MSCI Emerging Markets Small Cap UCITS ETF 0.14%
Equity
Emerging Markets
Small Cap
291
Vanguard ESG Developed Asia Pacific All Cap UCITS ETF (USD) Distributing 0.03%
Equity
Asia Pacific
Social/Environmental
25
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing 0.00%
Equity
World
Social/Environmental
485
iShares MSCI EM IMI Screened UCITS ETF USD (Dist) 0.02%
Equity
Emerging Markets
Social/Environmental
1,068
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.